Navigation Links
Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
Date:9/14/2009

nfections."

About Delafloxacin

Delafloxacin, a novel, broad spectrum, next-generation fluoroquinolone, has demonstrated better activity than other quinolones against Gram-positive bacteria, including isolates of MRSA that are quinolone-resistant. Recently, Rib-X has announced positive results from a Phase 2 trial utilizing the IV formulation of delafloxacin in complicated skin and skin structure infections (cSSSI). Delafloxacin successfully completed two previous Phase 2 trials with the oral formulation. In microbiological tests of large numbers of contemporary clinical isolates, the compound has been shown to be at least 32-fold more potent than levofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin against quinolone-resistant MRSA (MIC90 of = 0.5 ug/ml for delafloxacin compared to > 16 ug/ml for all other quinolones) and twice as potent as daptomycin against MRSA. Additionally, delafloxacin was shown to more potent than ciprofloxacin against N. gonorrhoeae (MIC90 of = 0.06 ug/ml for delafloxacin compared to > 16 ug/ml for ciprofloxacin). Delafloxacin has also been shown to be more potent than existing quinolones against a range of Gram-positive, anaerobic and Gram-negative organisms. Rib-X is currently developing both IV and oral formulations of delafloxacin for use in surgical prophylaxis and other therapeutic arenas within the over $9.9 billion hospital antibiotic market.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Compa
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
2. Rib-X Granted Key Antibiotic Patent in China
3. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Womens Hall of Fame
5. Merz Pharmaceuticals Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA
6. Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States
7. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
8. Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
9. Reportlinker Adds US and European Radiopharmaceuticals Market Report
10. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
11. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2014)... Calif. A single type of cell in the ... of invasive bladder cancer, according to researchers at the ... in mice, is the first to pinpoint the normal ... cancers. It,s also the first to show that most ... just one cell, and explains why many human bladder ...
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2
... Businesses Encouraged to Reduce Air Pollution, HARRISBURG, ... and its regional air quality partnerships have,forecast an ... in the,Berks/Lehigh, Liberty/Clairton, Philadelphia, Pittsburgh and Susquehanna,Valley regions., ... be code ORANGE for,ozone in the Berks/Lehigh Valley, ...
... brain are lost through disease or injury, neighboring cells begin ... the brain are able to produce new neurons. Patients with ... an area of the brain called the substantia nigra and ... these areas have not been well described because of limitations ...
... family reunion in Arkansas. The nurse and the research coordinator at The ... going West in search of the serum that binds this family. More ... ... Christine Demers and Areeba Sadiq set off for a family reunion in ...
... Program Encourages Kids to ,Eat Smart for a Great Start, ... ... ,Produce for Kids(R) (PFK), an organization that promotes the benefits of,healthy eating ... and tools that support the positive,development of the whole child - the ...
... N.J., Sept. 3 Teva,Pharmaceutical Industries Ltd. (Nasdaq: ... BRL ) announced today that, as expected, each ... referred to as a "second,request") from the U.S. ... acquisition of Barr. The parties have been cooperating ...
... 3 Z Trim Holdings,Inc. (Amex: ZTM ) issued ... September 3, 2008, To: Z Trim Shareholders, ... In this second installment of periodic updates intended to ... on the motives and,outcomes -- realized and anticipated -- behind ...
Cached Medicine News:Health News:Air Quality Action Day Forecast Thursday in All Regions 2Health News:New methods identify and manipulate 'newborn' cells in animal model of Parkinson's disease 2Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 2Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 3Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 4Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 5Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 2Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 3Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 4Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 5Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 6Health News:Teva and Barr Receive FTC Request for Additional Information 2Health News:Teva and Barr Receive FTC Request for Additional Information 3Health News:Teva and Barr Receive FTC Request for Additional Information 4Health News:Teva and Barr Receive FTC Request for Additional Information 5Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 2Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 3Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 4Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 5Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 6
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
A low viscosity type of bone cement, intended for syringe or cement gun application....
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
Medicine Products: